Utilization of a Microdevice for Psoriasis and Atopic Dermatitis

NOT YET RECRUITING

NCT07352566

PHASE4

Sponsor: University of California, San Francisco

Summary

This study is being done to test a microdevice, which is a small device designed to test drugs directly on skin conditions like atopic dermatitis (eczema) and psoriasis. The small device, about the size of a grain of rice, has up to 20 tiny reservoirs that hold medications that are approved by the Food and Drug Administration (FDA) for atopic dermatitis and psoriasis. Very small amounts of these medications will be released into the skin (at levels in your body much lower than are typically used). In this study, the device will be tested to see if it's safe and works well for predicting how the skin will react to standard treatments. We will also look at how these reactions are connected to genetic information and overall treatment results.

Official title: Utilization of a Cutaneous Therapy In Situ Microdevice

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

10

Start Date

2026-01-01

Completion Date

2030-06-01

Last Updated

2026-01-20

Healthy Volunteers

No

Conditions

Psoriasis Atopic Dermatitis

Interventions

DEVICE

In situ cutaneous microdevice

The small device, about the size of a grain of rice, has up to 20 tiny reservoirs that hold medications that are approved by the Food and Drug Administration (FDA) for atopic dermatitis and psoriasis. In this study, the device will be tested to see if it's safe and works well for predicting how the skin will react to standard treatments. The microdevice will contain a subset of the following: Triamcinolone, 5-fluorouracil, Calcipotriene, Tapinarof, Crisaborole, Tacrolimus, Adalimumab, Etanercept, Certolizumab, Infliximab, Secukinumab, Ixekizumab, Apremilast, Risankizumab, Ustekinumab, Hydroxychloroquine, Methotrexate, Mycophenolate, Azathioprine, Chloroquine, Cyclosporine, Tofacitinib, Deucravacitinib, Dupilumab, Tralokinumab, Guselkumab, Tildrakizumab, Baractinib, Abrocitinib, Upadacitinib, Lebrikizumab, Nemolizumab, Ruxolitinib, Bimekizumab, Roflumilast.

DRUG

Triamcinolone

DRUG

5-Fluorouracil

5-fluorouracil

DRUG

Calcipotriene

DRUG

Tapinarof

DRUG

Crisaborole

DRUG

Tacrolimus

DRUG

Adalimumab

DRUG

Etanercept

DRUG

Certolizumab

DRUG

Infliximab

DRUG

Secukinumab

DRUG

Ixekizumab

DRUG

Apremilast

DRUG

Risankizumab

DRUG

Ustekinumab

DRUG

Hydroxychloroquine

DRUG

Methotrexate

DRUG

Mycophenolate

DRUG

Azathioprine

DRUG

Chloroquine

DRUG

Cyclosporine

DRUG

Tofacitinib

DRUG

Deucravacitinib

DRUG

Dupilumab

DRUG

Tralokinumab

DRUG

Guselkumab

DRUG

Tildrakizumab

DRUG

Baractinib

DRUG

Abrocitinib

DRUG

Upadacitinib

DRUG

Lebrikizumab

DRUG

Nemolizumab

DRUG

Ruxolitinib

DRUG

Bimekizumab

DRUG

Roflumilast

Locations (1)

University of California, San Francisco

San Francisco, California, United States

Clinical Research Directory